Loading...
•
Jun 30, 2024
Organon Q2 2024 Earnings Report
Organon's financial performance remained stable with slight revenue growth, driven by Women's Health and Biosimilars, while Established Brands faced challenges.
Key Takeaways
Organon reported second-quarter revenue of $1.607 billion, flat year-over-year on an as-reported basis but up 2% ex-FX. Women's Health and Biosimilars showed growth, while Established Brands declined slightly. Net income was $195 million, or $0.75 per diluted share. The company is tracking well to its 2024 objectives.
Total revenue was $1.607 billion, flat year-over-year but increased 2% ex-FX.
Women’s Health revenue increased 3% driven by Nexplanon growth.
Biosimilars revenue grew 22% due to Hadlima uptake.
Net income was $195 million, or $0.75 per diluted share.
Organon
Organon
Forward Guidance
Full year 2024 financial guidance is presented on a non-GAAP basis, except revenue.